Glaucoma – Open Angle
Primary open-angle glaucoma is a chronic, progressive optic-neuropathy in which characteristic structural damage to the optic nerve head and thinning of the retinal nerve-fiber layer lead to irreversible visual-field loss despite an anatomically open anterior-chamber angle. It is the most common type of glaucoma, accounting for roughly three-quarters of the 68–70 million people living with glaucoma worldwide and affecting about 2 %–3 % of adults over forty; prevalence rises sharply with age and is highest in populations of African ancestry.
Symptoms
The disease is asymptomatic until late; peripheral visual-field defects encroach slowly, leaving central acuity intact so patients may note only difficulty with side vision, tripping, or dim adaptation. Acute symptoms such as pain or redness do not occur in open-angle glaucoma, so routine screening is essential.
Risk Factors
Advancing age, positive family history, African or Afro-Caribbean ancestry, Latino ethnicity, elevated baseline IOP, thin central corneal thickness (< 530 µm), high myopia, type 2 diabetes, systemic hypertension or nocturnal hypotension, obstructive sleep apnoea, prolonged corticosteroid exposure (topical, inhaled, systemic), and migraine with vasospastic phenomena increase susceptibility.
Diagnosis
Diagnosis integrates: (1) applanation tonometry showing IOP commonly—but not invariably—above 21 mm Hg; (2) optic-disc cupping, rim thinning, notching, disc haemorrhages, or asymmetry on slit-lamp biomicroscopy; (3) characteristic arcuate, nasal-step, or paracentral scotomas on automated perimetry; and (4) open irido-corneal angle on gonioscopy. Spectral-domain OCT quantifies retinal nerve-fiber and ganglion-cell-inner-plexiform-layer thickness and detects progression earlier than perimetry. Central corneal thickness is measured to refine true IOP. Secondary causes are excluded with history, examination, and sometimes ultrasound biomicroscopy or laboratory tests.
Treatment
Target IOP is set 20 %–50 % below baseline depending on stage and risk factors. First-line therapy is once-daily prostaglandin analogue eyedrops (latanoprost, tafluprost, travoprost) that enhance uveoscleral outflow; they lower IOP 25 %–33 % and have minimal systemic effects. If goal is not reached, adjunctive topical agents—β-blockers, α2-agonists, topical carbonic-anhydrase inhibitors, or rho-kinase inhibitors—are added or fixed-dose combinations used to improve adherence. Sustained-release options such as the intracameral bimatoprost implant (Durysta), which can maintain pressure control for a year or longer, offer drop-free therapy for selected patients. Laser trabeculoplasty (selective or micropulse) is recommended as primary or adjunctive treatment, particularly in drop-intolerant patients. Minimally invasive glaucoma surgery (MIGS) devices—including iStent infinite, approved for standalone use in refractory disease—create trabecular or suprachoroidal micro-bypasses and achieve modest pressure reductions with rapid visual recovery. Traditional filtering surgeries (trabeculectomy) or tube shunts provide the greatest IOP lowering when medical or laser measures fail. Neuroprotective and gene-based therapies remain investigational, although early trials of nicotinamide and brimonidine-citicoline implants show promise.
Outlook
Effective pressure control stabilises visual fields in 80 %–90 % of cases, and modern treatments allow most patients to retain driving vision for life. Nevertheless, up to 12 % progress to legal blindness in at least one eye, mainly from late presentation, non-adherence, or aggressive disease phenotype. Continuous monitoring every 3-12 months with optic-nerve imaging and perimetry is required because damage is irreversible.
Complications
Progressive visual-field constriction leads to tunnel vision, impaired night driving, falls, and depression. Surgical interventions can cause hypotony, bleb infection, cataract, or suprachoroidal haemorrhage, while topical therapy may induce ocular surface disease or systemic β-blocker effects such as bradycardia or bronchospasm.
Prevention
No proven primary prevention exists, but maintaining healthy blood pressure, regular aerobic exercise, smoking cessation, and control of diabetes or sleep apnoea may protect optic-nerve perfusion. Early detection through periodic eye examinations remains the only practical preventive measure against vision loss.
Support
Daily adherence to eyedrops is critical; strategies include smartphone reminders, colour-coded bottles, family supervision, and using fixed-combination drops to reduce burden. Wearing seatbelts to protect remaining vision, improving home lighting, marking steps, and using wide-angle mirrors aid adaptation. Patients benefit from low-vision counselling and driver-licence assessments when fields decline.
Sources
The information presented above is supported by reputable medical sources and research publications. These references provide additional clinical insights and evidence-based findings for healthcare professionals and individuals seeking comprehensive understanding of this medical condition.
